Nu-Med Plus (NUMD) 10% Owner Fred Tejada Acquires ~17.5M Shares

What Happened

• Fred Tejada, reported as a 10% owner of Nu‑Med Plus, acquired a total of 17,511,032 shares on July 8, 2026. Transactions reported include:
  • 16,381,250 shares — "other acquisition or disposition" (code J), price N/A (acquired).
  • 1,000,000 shares — grant/award (code A) issued at $0.00 (acquired) as compensation for services.
  • 129,782 shares — derivative grant/award (code A), price N/A (acquired); these are derivative securities referenced in the filing.
• These were acquisitions/awards (not sales). No cash values other than the $0.00 compensation award were reported.

Key Details

• Transaction date: July 8, 2026. Form filed August 25, 2026 (the Form 4 filing was late relative to the typical 2‑business‑day reporting requirement).
• Prices reported: 1,000,000 shares at $0.00; the 16,381,250 and 129,782 share items show "N/A" price (issued as part of share exchange/other transactions).
• Shares acquired total ≈ 17,511,032 shares (sum of all reported acquisitions).
• Shares owned after transaction: not specified in the provided filing details.
• Notable footnotes:
  • Voting Agreement (F1–F3): Tejada was granted an irrevocable proxy to vote shares held by several affiliated Voting Shareholders; this may give him shared voting power over certain affiliated holdings (he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest).
  • Awards were issued as consideration for services and/or pursuant to a June 29, 2026 Share Exchange Agreement (F5, F7).
  • Derivative securities: Series A Preferred described (F6, F8, F9) — convertible into common at 1:20 (one Series A → 20 common), no expiration, and subject to a conversion cap that prevents conversions that would cause the holder to beneficially own more than 4.999% of outstanding common stock (can be increased up to 9.999% with notice, subject to a 61‑day delay).
  • Series X Preferred (if applicable) carries enhanced voting (100 votes per share) per filing note (F4).
• Filing timeliness: late filing — transaction occurred July 8, 2026; Form 4 was filed August 25, 2026. Late reporting reduces near‑term transparency for investors.

Context

• These entries reflect acquisitions/awards (including compensation and share‑exchange consideration), not open‑market purchases or sales. Awards issued at $0.00 are typical for compensation grants and do not by themselves indicate an immediate cash investment by the insider.
• The derivative entry represents preferred shares convertible into common stock (see conversion ratio and the 4.999% beneficial ownership cap). Conversions and voting rights can materially affect voting power even if common‑share ownership is limited.
• As a 10% owner with an irrevocable proxy over affiliated holders under a Voting Agreement, Tejada may have enhanced voting influence; that is a governance consideration distinct from direct economic ownership.